Merck continues to expect full-year 2012 revenues to be at or near 2011 levels on a constant currency basis. At current exchange rates, sales would be affected unfavorably by approximately 6 percent for the third quarter and more than 3 percent for the full year.

In addition, the company expects full-year 2012 non-GAAP R&D expenses to be slightly higher than the 2011 level. The company now expects the full-year 2012 non-GAAP tax rate to be approximately 25 percent.

A reconciliation of anticipated 2012 EPS as reported in accordance with GAAP to non-GAAP EPS that excludes certain items is provided in the table below.
   

$ in millions, except EPS amounts
 

Full-Year 2012
GAAP EPS   $2.04 to $2.30

Difference 3
  1.71 to 1.55
Non-GAAP EPS that excludes items listed below   $3.75 to $3.85
 
     
Acquisition-related costs 4   $5,200 to $4,900
Restructuring costs   1,100 to 800
Net decrease (increase) in income before taxes   6,300 to 5,700
Estimated income tax (benefit) expense   (1,110) to (985)
Decrease (increase) in net income   $5,190 to $4,715

Total Employees

As of June 30, 2012, Merck had approximately 84,000 employees worldwide.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts